Total Payments
$1.5M
2024 Payments
$144,722
Companies
84
Transactions
4,671
Medicare Patients
14,318
Medicare Billing
$16.0M
Payment Breakdown by Category
Other$1.3M (81.7%)
Travel$121,035 (7.9%)
Consulting$80,812 (5.3%)
Food & Beverage$77,424 (5.1%)
Education$1,044 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 468 | 68.7% |
| Honoraria | $197,317 | 101 | 12.9% |
| Travel and Lodging | $121,035 | 255 | 7.9% |
| Consulting Fee | $80,812 | 32 | 5.3% |
| Food and Beverage | $77,424 | 3,775 | 5.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,000 | 1 | 0.1% |
| Education | $1,044 | 39 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $331,815 | 298 | $0 (2019) |
| ABBVIE INC. | $312,943 | 678 | $0 (2024) |
| Horizon Therapeutics plc | $122,975 | 323 | $0 (2023) |
| Horizon Pharma plc | $89,578 | 159 | $0 (2018) |
| Janssen Biotech, Inc. | $87,640 | 437 | $0 (2024) |
| Lilly USA, LLC | $78,506 | 162 | $0 (2024) |
| GlaxoSmithKline, LLC. | $73,041 | 149 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $66,553 | 96 | $0 (2019) |
| PFIZER INC. | $55,654 | 406 | $0 (2024) |
| Amgen Inc. | $47,961 | 251 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $144,722 | 479 | Janssen Biotech, Inc. ($49,100) |
| 2023 | $126,986 | 456 | Janssen Biotech, Inc. ($31,033) |
| 2022 | $155,523 | 553 | ABBVIE INC. ($42,681) |
| 2021 | $109,682 | 489 | Horizon Therapeutics plc ($29,502) |
| 2020 | $92,775 | 438 | AbbVie Inc. ($17,676) |
| 2019 | $302,803 | 777 | Celgene Corporation ($88,722) |
| 2018 | $252,143 | 620 | Celgene Corporation ($94,393) |
| 2017 | $348,131 | 859 | Celgene Corporation ($148,701) |
All Payment Transactions
4,671 individual payment records from CMS Open Payments — Page 1 of 187
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Rare Disease | ||||||
| 12/19/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $13.38 | General |
| 12/17/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $9.92 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $10.88 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: Immunology | ||||||
| 12/11/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: Analgesic | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.75 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $78.11 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 3,160 | 541,676 | $10.4M | $4.3M |
| 2022 | 33 | 3,639 | 486,695 | $8.7M | $3.8M |
| 2021 | 34 | 3,990 | 439,252 | $7.7M | $4.0M |
| 2020 | 29 | 3,529 | 371,457 | $6.9M | $4.0M |
Total Patients
14,318
Total Services
1,839,080
Medicare Billing
$16.0M
Procedure Codes
129
All Medicare Procedures & Services
129 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 132 | 313,200 | $3.8M | $1.2M | 32.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 65 | 31,875 | $2.4M | $1.1M | 44.6% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 41 | 104,040 | $1.0M | $487,616 | 46.9% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 69 | 45,100 | $1.4M | $473,159 | 35.0% |
| J0490 | Injection, belimumab, 10 mg | Office | 2023 | 13 | 7,848 | $465,920 | $312,463 | 67.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 20 | 18,480 | $231,000 | $146,968 | 63.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 179 | 1,076 | $219,400 | $122,960 | 56.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 68 | 5,760 | $156,600 | $103,631 | 66.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 133 | 1,574 | $236,100 | $101,067 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 524 | 807 | $102,645 | $54,859 | 53.4% |
| J7329 | Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | Office | 2023 | 48 | 5,975 | $149,375 | $41,608 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 255 | 349 | $53,340 | $33,053 | 62.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 209 | 450 | $51,968 | $26,277 | 50.6% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 106 | 152 | $30,600 | $14,093 | 46.1% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2023 | 19 | 992 | $24,625 | $13,256 | 53.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 283 | 1,051 | $52,550 | $12,483 | 23.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 194 | 258 | $26,150 | $10,812 | 41.3% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 364 | 1,923 | $19,230 | $9,721 | 50.6% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2023 | 53 | 94 | $14,100 | $9,696 | 68.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $11,525 | $6,451 | 56.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $6,575 | $4,284 | 65.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 53 | 53 | $9,000 | $4,207 | 46.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 28 | $6,300 | $3,573 | 56.7% |
| 20604 | Aspiration and/or injection of fluid from small joint using ultrasound guidance | Office | 2023 | 19 | 21 | $4,200 | $1,494 | 35.6% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 23 | 28 | $2,115 | $1,125 | 53.2% |
About Dr. Richard Haddad, MD
Dr. Richard Haddad, MD is a Specialist healthcare provider based in Red Bank, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1750382800.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Haddad, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $144,722 received in 2024. These payments were reported across 4,671 transactions from 84 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Haddad has provided services to 14,318 Medicare beneficiaries, totaling 1,839,080 services with total Medicare billing of $16.0M. Data is available for 4 years (2020–2023), covering 129 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Red Bank, NJ
- Active Since 08/10/2005
- Last Updated 10/22/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1750382800
Products in Payments
- Otezla (Drug) $372,513
- RINVOQ (Biological) $117,340
- RAYOS (Drug) $98,608
- TREMFYA (Drug) $79,624
- ACTHAR (Biological) $77,654
- TALTZ (Drug) $73,114
- BENLYSTA (Biological) $73,041
- KRYSTEXXA (Biological) $61,505
- SIMPONI ARIA (Biological) $44,532
- XELJANZ (Drug) $42,451
- KRYSTEXXA (Drug) $41,663
- KEVZARA (Drug) $39,210
- SAPHNELO (Biological) $37,483
- Rasuvo (Drug) $23,929
- SKYRIZI (Biological) $23,441
- COSENTYX (Biological) $23,425
- Humira (Biological) $22,690
- Actemra (Biological) $19,374
- Rinvoq (Biological) $15,647
- RINVOQ (Drug) $15,550
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Red Bank
Dr. Edward Allegra, Md, MD
Specialist — Payments: $273,313
Specialist $273,313
Usha Niranjan, M.d, M.D
Specialist — Payments: $1,954
Specialist $1,954
Dr. Diana Trusky, Md, MD
Specialist — Payments: $1,387
Specialist $1,387
Mr. Robert Gabel, Md, MD
Specialist — Payments: $414.30
Specialist $414.30
Dr. Thomas Theocharides, Md, MD
Specialist — Payments: $339.86
Specialist $339.86
Dr. Frederick Stone, M.d, M.D
Specialist
Specialist